rotigotine transdermal system

rotigotine transdermal system

(ro-ti-go-teen) ,


(trade name)


Therapeutic: antiparkinson agents
Pharmacologic: dopamine agonists
Pregnancy Category: C


Symptomatic management of idiopathic Parkinson's disease.Moderate-to-severe primary restless leg syndrome


Acts as an agonist of dopamine in the CNS, primarily at D2 receptor sites.

Therapeutic effects

Improvement in symptoms of Parkinson's disease.
Decreased leg restlessness


Absorption: 46% absorbed from patch over 24 hr.
Distribution: Unknown.
Protein Binding: 90%
Metabolism and Excretion: Mostly metabolized and excreted in urine as metabolites (71%); 23% excreted in feces.
Half-life: Biphasic: initial half-life 3 hr; terminal half-life 5–7 hr.

Time/action profile (plasma concentrations)

Transdermal1–3 hr15–18 hr (range 4–27 hr)24 hr


Contraindicated in: Hypersensitivity to rotigotine or sulfites;
Use Cautiously in: Severe cardiovascular disease (may ↑ risk of postural hypotension or syncope); Severe hepatic impairment; Major psychotic disorder Obstetric: May be excreted in breast milk and pose a risk of adverse effects in the infant; use only if maternal benefits outweigh risk to fetus; Pediatric: Safety not established;

Adverse Reactions/Side Effects

Central nervous system

  • drowsiness
  • insomnia (most frequent)
  • aggression
  • agitation
  • confusion
  • delirium
  • delusions
  • disorientation
  • dizziness
  • hallucinations
  • headache
  • paranoid ideation
  • sudden sleep attacks
  • urges (gambling, sexual)


  • hypertension
  • peripheral edema
  • postural hypotension
  • syncope
  • tachycardia


  • nausea (most frequent)
  • vomiting (most frequent)
  • anorexia
  • dry mouth
  • dyspepsia


  • urinary incontinence


  • application site reactions (most frequent)
  • melanoma
  • pruritus
  • purpura
  • sweating


  • weight gain


  • leg pain


  • abnormal gait
  • ataxia
  • dyskinesia
  • hypertonia
  • hypoesthesia
  • neuralgia
  • paresthesia


  • fever


Drug-Drug interaction

Concurrent use of dopamine antagonists including some antipsychotics or metoclopramide may ↓ effectiveness.


Parkinson's Disease

Transdermal (Adults) Early-stage—2 mg/24 hr initially, may ↑ by 2 mg/24 hr weekly, up to 6 mg/24 hr; Advanced-stage—4mg/24 hr initially, may ↑ by 2 mg/24 hr weekly, up to 8 mg/24 hr.

Restless Legs Syndrome

Transdermal (Adults) 1 mg/24 hr initially, may ↑ by 1 mg/24 hr weekly, up to 3 mg/24 hr.


Transdermal system: 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr, 4 mg/24 hr, 6 mg/24 hr, 8 mg/24 hr

Nursing implications

Nursing assessment

  • Assess for allergy to sulfite, may be more common in asthmatics.
  • Assess frequently for drowsiness, a common side effect of rotigotine. Episodes of falling asleep during activities that require active participation may occur without warning. Patients may not acknowledge drowsiness unless directly questioned about drowsiness during specific activities. May occur as late as 1 year after initiation of therapy. Assess patient for concomitant medications that have sedating effects. May require discontinuation of therapy.
  • Monitor BP, sitting and standing, periodically during therapy, especially during dose escalation. May also cause syncope.
  • Assess for application site reactions (erythema, edema, pruritus). If persistent, (more than a few days), increasing in severity, or spreading outside application site, determine risk/benefit ratio. If generalized skin reaction (allergic macular-papular rash) occurs, discontinue rotigotine.
  • Assess for hallucinations. May require discontinuation.
  • Monitor for weight gain; usually associated with peripheral edema.
  • Assess for development of new or increased gambling urges, sexual urges, or other urges during therapy.
  • Parkinson's Disease: Assess patient for signs and symptoms of Parkinson’s disease (tremor, muscle weakness and rigidity, ataxia) before and throughout therapy.
  • Restless Leg Syndrome: Assess sleep patterns and frequency of restless leg disturbances.
  • Lab Test Considerations: May cause ↓ hemoglobin and serum albumin and glucose levels.
    • May cause ↑ BUN and GGT levels.

Potential Nursing Diagnoses

Impaired physical mobility (Indications)
Risk for injury (Adverse Reactions)


  • Transdermal: Apply once daily to clean, dry, intact skin on abdomen, thigh, hip, flank, shoulder, or upper arm. Hold in place for 20–30 seconds to make sure of good contact, especially around edges. If applied to hairy area, shave area at least 3 days prior to application. Do not apply to areas that could be rubbed by tight clothing, are under a waistband, or to skin folds. Do not apply to skin that is red, irritated, or impaired. Do not apply creams, lotions, ointments, oils, or powders to skin areas where patch will be placed. Wash hands following application to remove any drug and do not touch eyes. Rotate patch site daily; do not use same application site more than once every 14 days. Do not cut or damage patch. Remove patch slowly and carefully to avoid irritation. Fold over so it sticks to itself and discard. Wash application site with soap and water to remove drug or adhesive. May use baby or mineral oil to remove excess residue. Avoid using alcohol or other solvents, may cause skin irritation. If therapy is discontinued, decrease gradually by 2 mg/24 hrs every other day until complete withdrawal.

Patient/Family Teaching

  • Instruct patient on proper method of patch application. Advise patient to wear patch continuously for 24 hrs and to apply system at the same time each day; if patch change is missed, apply as soon as possible and replace at usual time the following day. Patients may bathe, shower or swim with patch on. If patch falls off, apply a new on immediately to a different site and change according to regular schedule. Do not stop therapy without consulting health care professional. withdrawal.
  • May cause drowsiness and unexpected episodes of falling asleep. Caution patient to avoid driving and other activities requiring alertness until response to medication is known. Advise patient to notify health care professional if episodes of falling asleep occur.
  • Advise patient to notify health care professional if application site reaction occurs.
  • Inform patient that rotigotine may cause hallucinations.
  • Advise patient to remove rotigotine patch prior to magnetic resonance imaging or cardioversion.
  • Caution patient to avoid exposing patch to external heat (heating pad, electric blanket, heat lamp, sauna, hot tub, heated water bed, prolonged direct sunlight).
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications or alcohol.
  • Advise patient to notify health care professional if they experience new or increased gambling, sexual or other intense urges during therapy. May require discontinuation.
  • Advise patient to have health care professional check their skin for skin cancer regularly due to increase risk of melanoma.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Improvement in signs and symptoms of early-stage Parkinson's disease.
  • Decrease in restless legs and improved sleep.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study.
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: Results of two open-label extension studies, CLEOPATRA-PD and PREFER.
Neupro (rotigotine transdermal system): Full prescribing information.
Biopharmaceutical company UCB (BRU:UCB.BR) (FRA:UNC.F) announced today that Neupro (Rotigotine Transdermal System) is now available in US pharmacies.
LeWitt PA, Lyons KE, Pahwa R 2007 Advanced Parkinson's disease treated with rotigotine transdermal system Neurology 68 (16) 1262-1267
Called Neupro patch (rotigotine transdermal system), the once-a-day patch contains rotigotine, a drug that mimics the effects of the neurotransmitter dopamine to counteract the loss of dopamine-producing brain cells that causes PD.